StockData
Aptevo Therapeutics Inc. logo

Aptevo Therapeutics Inc. (APVO) stock

APVONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.46−0.09 (-15.97%)

Close on Nov 17, 2026Market cap $830.71KP/E –Yield –

Aptevo Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Aptevo Therapeutics's total assets was $14.52M at Jun 30, 2026. For fiscal 2025 it was $27.19M, up 74.4% from the year before. Over ten years it grew -14.3% a year on average. The highest annual figure on record is $127.77M in fiscal 2015.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$27.19M+74.4%
FY2024Dec 31, 2024$15.59M-37.2%
FY2023Dec 31, 2023$24.84M-27.4%
FY2022Dec 31, 2022$34.22M-39.6%
FY2021Dec 31, 2021$56.60M+5.7%
FY2020Dec 31, 2020$53.55M+0.3%
FY2019Dec 31, 2019$53.41M-20.9%
FY2018Dec 31, 2018$67.49M-42.3%
FY2017Dec 31, 2017$117.01M+27.4%
FY2016Dec 31, 2016$91.86M-28.1%
FY2015Dec 31, 2015$127.77M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$14.52M-7.1%
Q1 FY2026Mar 31, 2026$19.90M+138.6%
Q4 FY2025Dec 31, 2025$27.19M+74.4%
Q3 FY2025Sep 30, 2025$27.00M+78.2%
Q2 FY2025Jun 30, 2025$15.62M+4.7%
Q1 FY2025Mar 31, 2025$8.34M-52.7%
Q4 FY2024Dec 31, 2024$15.59M-37.2%
Q3 FY2024Sep 30, 2024$15.15M-44.2%
Q2 FY2024Jun 30, 2024$14.92M-48.4%
Q1 FY2024Mar 31, 2024$17.63M-49.6%
Q4 FY2023Dec 31, 2023$24.84M-27.4%
Q3 FY2023Sep 30, 2023$27.13M-14.4%
Q2 FY2023Jun 30, 2023$28.91M-25.5%
Q1 FY2023Mar 31, 2023$34.97M-22.6%
Q4 FY2022Dec 31, 2022$34.22M-39.6%
Q3 FY2022Sep 30, 2022$31.70M-50.5%
Q2 FY2022Jun 30, 2022$38.80M-45.7%
Q1 FY2022Mar 31, 2022$45.18M-34.3%
Q4 FY2021Dec 31, 2021$56.60M+5.7%
Q3 FY2021Sep 30, 2021$64.01M+71.0%
Q2 FY2021Jun 30, 2021$71.47M+286.2%
Q1 FY2021Mar 31, 2021$68.75M+172.4%
Q4 FY2020Dec 31, 2020$53.55M+0.3%
Q3 FY2020Sep 30, 2020$37.42M-38.2%
Q2 FY2020Jun 30, 2020$18.51M-72.0%
Q1 FY2020Mar 31, 2020$25.24M-68.8%
Q4 FY2019Dec 31, 2019$53.41M-20.9%
Q3 FY2019Sep 30, 2019$60.56M-23.3%
Q2 FY2019Jun 30, 2019$66.13M-26.5%
Q1 FY2019Mar 31, 2019$80.84M-19.3%
Q4 FY2018Dec 31, 2018$67.49M-42.3%
Q3 FY2018Sep 30, 2018$78.93M-39.8%
Q2 FY2018Jun 30, 2018$90.00M+3.6%
Q1 FY2018Mar 31, 2018$100.21M+2.5%
Q4 FY2017Dec 31, 2017$117.01M+27.4%
Q3 FY2017Sep 30, 2017$131.02M+30.2%
Q2 FY2017Jun 30, 2017$86.89M–
Q1 FY2017Mar 31, 2017$97.79M–
Q4 FY2016Dec 31, 2016$91.86M–
Q3 FY2016Sep 30, 2016$100.62M–

More Aptevo Therapeutics figures

See a number that looks wrong?